Trial intelligence / Profile preview

Blossom: YM178 (Mirabegron) in Overactive Bladder

NCT01604928Phase 2Completed

Sponsor
Astellas Pharma
Start
Apr 2004
Primary completion
Jan 2005
Modality
Small Molecules
Countries
6
01

Overview

A Phase 2 trial of mirabegron in overactive bladder (OAB), sponsored by Astellas Pharma. Started Apr 2004; status: completed.

02

Drugs

mirabegron
03

Conditions

overactive bladder (OAB)

Beyond the preview

Go deeper on NCT01604928.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01604928.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call